Busulfan, Fludarabine, and Alemtuzumab As a Reduced Toxicity Regimen for Children with Malignant and Nonmalignant Diseases Improves Engraftment and Graft-versus-Host Disease without Delaying Immune Reconstitution
作者单位:Department of Surgery, University of California San Francisco, San Francisco, CA, United States[1]Department of Pediatrics, UCSF Benioff Children's Hospital, University of California San Francisco[2]Department of Clinical Pharmacy, University of California San Francisco, San Francisco, CA, United[3]Department of Pediatrics, Floating Hospital for Children, Tufts Medical Center, Boston, MA, United[4]